Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

NCT05286060 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: GX-188E, GX-I7, Pembrolizumab
DRUG: GX-188E, Pembrolizumab
DRUG: GX-188E, GX-I7, Pembrolizumab
DRUG: GX-188E, GX-I7

Sponsor

Yonsei University

Collaborators

[object Object]
[object Object]